Skip to main content
. 2022 Jul 3;10(7):1071. doi: 10.3390/vaccines10071071

Figure 2.

Figure 2

Immune responses against SARS-CoV-2 in the BBIBP-CorV-primed group. (A) The total circulating RBD Ig of SARS-CoV-2 (U/mL), and (B) circulating anti-RBD IgG of SARS-CoV-2 (BAU/mL). The lines represent GMTs. The dotted lines represent the cutoff titers; p < 0.01 (**).